Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0911 in Cancer Treatment-Induced Thrombocytopenia
NCT06456528Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of QL0911 in chemotherapy-induced thrombocytopenia (CIT), sponsored by Qilu Pharmaceutical. Started Oct 2024; status: recruiting.
02
Drugs
QL0911
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT06456528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456528.